<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627833</url>
  </required_header>
  <id_info>
    <org_study_id>MRosewich</org_study_id>
    <nct_id>NCT02627833</nct_id>
  </id_info>
  <brief_title>Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO</brief_title>
  <acronym>FRABO-03</acronym>
  <official_title>Lungfunction, Lung Clearance Index, Bronchial Inflammation and Epigenetics of Patients With Bronchiolitis Obliterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bronchiolitis obliterans is a chronic disease in which a persistent inflammatory process
      leads to obliteration of the small airways. Pulmonary function tests (body plethysmography
      with DLCO, lung clearance index) are performed and the fraction of exhaled nitric oxide is
      measured. A blood test is following to determine the inflammatory status und collect miRNA.
      Induced Sputum will be obtained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare miRNA pattern, lung function values, bronchial
      inflammation and the Lung clearance index of Patients with Bronchiolitis obliterans aged
      between 6 up to 30 years of age with a matched control group.

      The sputum samples will be processed and quantitatively analyzed to get a profile of the
      cytological composition.

      Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction
      (qRT-PCR) and by cytometric bead assay (CBA). miRNA samples will be collected, processand
      compared with the miRNA database at http://www.mirbase.org/

      Methods and Work Programme:

        -  Measurement of nitric oxide in expired air (FeNO)

        -  Lung function testing with spirometry and body plethysmography

        -  Lung clearance index (LCI)

        -  Bronchodilation

        -  Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of
           the non-specific pulmonary defense system), miRNA analysis

        -  Induced sputum for inflammatory mediators and microbiological investigations
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA Status</measure>
    <time_frame>single day observation</time_frame>
    <description>Blood sample to determine candidate miRNA for Bronchiolitis obliterans</description>
  </primary_outcome>
  <other_outcome>
    <measure>Lung clearance index (LCI)</measure>
    <time_frame>single day observation</time_frame>
    <description>Determine Lung clearance index with the Oxygen washout method</description>
  </other_outcome>
  <other_outcome>
    <measure>FVC [%-pred.]</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare FVC [%-pred.] of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>FEV1 [%-pred.]</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare FEV1[%-pred.] of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Tiffeneau Index</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare Tiffeneau-Index of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>sRtot [%-pred.]</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare sRtot[%-pred.] of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>RV/TLC [%-pred.]</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare RV/TLC[%-pred.] of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>DLCO [%-pred.]</measure>
    <time_frame>single day observation</time_frame>
    <description>Compare difffusion capacity of the lung for CO [%-pred.] of BO Patients with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6 (pg/ml)</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing IL-6 in Serum of patients with BO with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-8 (pg/ml</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing IL-8 in Serum of patients with BO with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Il-17 (pg/ml)</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing IL-17 in Serum of patients with BO with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>CrP (mg/dl)</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing CrP in Serum of patients with BO with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>FeNO ppb</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing FeNO in exhaled air of patients with BO with a healthy control group</description>
  </other_outcome>
  <other_outcome>
    <measure>Sputum cell count</measure>
    <time_frame>single day observation</time_frame>
    <description>Comparing sputum cell counts of patients with BO with a healthy control group</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Subject Group</arm_group_label>
    <description>Patients suffering from Bronchiolitis Obliterans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Age and sex matched control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation</intervention_name>
    <description>Record lung function, Lung clearance index, inflammatory status</description>
    <arm_group_label>Subject Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cells of induced Sputum, blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the assured diagnose of Bronchiolitis Obliterans and controls without this
        disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  age between 6 an 35 years

          -  known bronchiolitis obliterans (Group Bronchiolitis)/ no Bronchiolitis Obliterans
             (Group matched controls)

          -  ability to perform lung function tests and inhale correctly

        Exclusion Criteria:

          -  &lt;6 years of age

          -  &gt;35 years of age

          -  acute systemic or bronchial inflammation

          -  other chronic diseases or infection (e.g. HIV, Tbc, malignoma)

          -  pregnancy

          -  alcohol, drug or illegal drug abuse

          -  disability to register the range and consequences of the study

          -  actual participation in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Rosewich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Rosewich, MD</last_name>
    <phone>+49-69-6301</phone>
    <phone_ext>5381</phone_ext>
    <email>Martin.rosewich@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital, Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Rosewich, MD</last_name>
      <phone>49-69-6301</phone>
      <phone_ext>5381</phone_ext>
      <email>Martin.Rosewich@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Zielen, MD, PhD</last_name>
      <phone>49-69-6301</phone>
      <phone_ext>83063</phone_ext>
      <email>Stefan.Zielen@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Rosewich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Zielen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kurland G, Michelson P. Bronchiolitis obliterans in children. Pediatr Pulmonol. 2005 Mar;39(3):193-208. Review.</citation>
    <PMID>15635614</PMID>
  </reference>
  <reference>
    <citation>Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung transplantation: a review. Chest. 1998 Nov;114(5):1411-26. Review.</citation>
    <PMID>9824023</PMID>
  </reference>
  <reference>
    <citation>Moonnumakal SP, Fan LL. Bronchiolitis obliterans in children. Curr Opin Pediatr. 2008 Jun;20(3):272-8. doi: 10.1097/MOP.0b013e3282ff62e9. Review.</citation>
    <PMID>18475095</PMID>
  </reference>
  <results_reference>
    <citation>Pichler M, Herrmann G, Schmidt H, Ahrens P, Zielen S. Persistent adenoviral infection and chronic obstructive bronchitis in children: is there a link? Pediatr Pulmonol. 2001 Nov;32(5):367-71.</citation>
    <PMID>11596161</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosewich M, Zissler UM, Kheiri T, Voss S, Eickmeier O, Schulze J, Herrmann E, Dücker RP, Schubert R, Zielen S. Airway inflammation in children and adolescents with bronchiolitis obliterans. Cytokine. 2015 May;73(1):156-62. doi: 10.1016/j.cyto.2014.10.026. Epub 2015 Mar 6.</citation>
    <PMID>25748838</PMID>
  </results_reference>
  <results_reference>
    <citation>Motameny S, Wolters S, Nürnberg P, Schumacher B. Next Generation Sequencing of miRNAs - Strategies, Resources and Methods. Genes (Basel). 2010 Jun 3;1(1):70-84. doi: 10.3390/genes1010070.</citation>
    <PMID>24710011</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. med. Martin Rosewich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>induced Sputum</keyword>
  <keyword>lung clearance index</keyword>
  <keyword>miRNA</keyword>
  <keyword>inflammation</keyword>
  <keyword>chronic lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

